Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates
Q3 2024 Total Revenue of $141.5M, a 37% Increase Year-over-Year
Amicus Therapeutics
Manufacturing · New Jersey, United States · 517 Employees
View Company Info for Free
About
Headquarters
47 Hulfish St, Princeton, New Jersey, 08542, Un...Phone Number
(609) 662-2000Website
www.amicusrx.comRevenue
$455.7 MillionStock Symbol
FOLDIndustry
Most Recent Scoops
Oct 10 2024
Open Position
Sep 20 2024
Open Position
Highlights
$475M
Total Funding Amount
$400M
Most Recent Funding Amount
2
Number of Funding Rounds
Who is Amicus Therapeutics
Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases.Read more
Amicus Therapeutics Org Chart
Is Amicus Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Amicus Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Amicus Therapeutics has new funding data
Check if Amicus Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Amicus Therapeutics launches new products
Check out if Amicus Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Amicus Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Amicus Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Amicus Therapeutics had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Amicus Therapeutics
Compare insights from companies similar to Amicus Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Amicus Therapeutics
$455.7M
517
Amicus Therapeutics financials insights
Gather financial insights about Amicus Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Amicus Therapeutics Employee Growth Rate
View Amicus Therapeutics’s full employee growth data
Percentage of growth
1st year Mask
2nd year Mask
Amicus Therapeutics Tech Stack
A closer look at the technologies used by Amicus Therapeutics
Most Recent Scoops
Oct 10 2024
Open Position
Sep 26 2024
Open Position
Sep 20 2024
Open Position
Sep 13 2024
Open Position
Sep 12 2024
Award
Award, Employee Engagement, Employee Relations, Employee Retention, Workforce Management, Bioengineering, Pharmaceuticals, Company Culture & Policy, Diversity & Inclusion, HR Operations, Operations, Organizational Development, Talent Management
Amicus Therapeutics News & Media
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November.Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024
PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2024.Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva
Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037 Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024
PRINCETON, N.J., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that three posters highlighting its development program for Pompe disease will be included at the 29th Annual Congress of the World Muscle Society being held October 8-12, 2024 in Prague, Czechia.
Read more news
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Frequently Asked Questions Regarding Amicus Therapeutics
Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases.... Read More
